Loading...
•
Sep 30, 2021
Arvinas Q3 2021 Earnings Report
Arvinas reported financial results for the third quarter ended September 30, 2021, and provided a corporate update, highlighting the collaboration with Pfizer and progress in clinical trials.
Key Takeaways
Arvinas reported Q3 2021 financial results, including revenues of $9.3 million and a net loss of $46.8 million. The company highlighted its collaboration with Pfizer and advancements in its clinical-stage programs, particularly ARV-471 and ARV-110.
Initiated Phase 1b combination trial with ARV-110 and abiraterone for mCRPC.
Completed global collaboration with Pfizer, receiving $650 million upfront and a $350 million equity investment.
Cash, cash equivalents, restricted cash and marketable securities were $1,549.0 million as of September 30, 2021.
Intends to initiate the Phase 1b combination study with everolimus, potentially as part of a planned umbrella study with multiple combination agents with Pfizer, as well as the neoadjuvant study, in 2022.
Revenue by Segment
Forward Guidance
Arvinas anticipates several milestones, including presenting data from ARV-471 and ARV-110 trials, initiating Phase 3 trials for ARV-471, and announcing Phase 1 data for ARV-766.
Positive Outlook
- Present Phase 1 dose escalation trial data (San Antonio Breast Cancer Symposium, December 2021)
- Present data from the VERITAC Phase 2 expansion trial (200 and 500 mg) (2022)
- Present safety data from the Phase 1b combination study with palbociclib (2022)
- Initiate multiple Phase 3 trials in metastatic breast cancer (as monotherapy and in combination) (2022)
- Initiate Phase 1b combination trial with everolimus in 2L/3L metastatic breast cancer, potentially as part of a planned umbrella study with Pfizer to explore multiple combination agents (2022)
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...